Richard Zimmermann on the Promise of Astatine-211 in the Future of Nuclear Medicine
In this thought-provoking article, nuclear medicine expert Richard Zimmermann explores the growing momentum behind Astatine-211 as a next-generation radionuclide for targeted alpha therapy. Drawing on decades of industry insight and recent advances in production, radiochemistry, and clinical application, Zimmermann examines whether At-211 is poised to become a game-changing player in radiopharmaceutical development—and what still needs to happen to make it a reality.
